2nd Oct 2006 07:01
Sinclair Pharma PLC02 October 2006 Sinclair Pharma plc announces AtopiclairTM marketing agreement with Intendis, in eight major territories Godalming UK, 2 October 2006: Sinclair Pharma plc ("Sinclair") theinternational specialty pharmaceutical company, has concluded a marketingagreement for its atopic dermatitis (eczema) product, AtopiclairTM, withIntendis GmbH, for eight major territories in the EU and worldwide. Intendis GmbH ("Intendis"), a leading Berlin-based global pharmaceutical companyspecialising in dermatology, is part of the global company Schering AG.Intendis will pay Sinclair upfront licensing fees and milestone payments and amargin on product sales. The agreement will give Sinclair its first product sales in Russia and isSinclair's most significant commercial deal for AtopiclairTM outside the USA.Intendis will market the product under the brand name Zarzenda(R), selling todermatologists, paediatricians and GPs. The product will be sold by Intendisexclusively in Russia, Brazil, Mexico and Austria and semi-exclusively inGermany, Spain, Italy and France. The deal includes an option to includePoland and some other territories in the future. The semi-exclusive deal in the key EU territories will allow Sinclair tocommercialise the product as AtopiclairTM in those markets. Sinclair currentlysells AtopiclairTM directly through its sales and marketing operation in Italyand plans to launch it in France and Portugal in 2007. Through co-marketing,Sinclair anticipates that there will be fast product introduction and a broadercoverage of potential prescribers. AtopiclairTM introduces a new concept into the management of atopic dermatitis;the clinically-proven, multcomponent treatment of a condition that ischaracterised by many different signs and symptoms. The existing market isdominated by topical products with a single active ingredient. By introducingAtopiclairTM under two brands, Sinclair intends to create a new market sectorwithin dermatology. Commenting Sinclair's CEO Dr Michael Flynn Said: "Intendis is a leading dermatology company whose sales footprint bothcompliments and strengthens our own presence in Europe and introduces AtopiclairTM into major new markets. With this co-marketing agreement with such a strongdermatology company in Europe, we are aiming to establish a new class ofnon-steroidal treatment of atopic dermatitis. AtopiclairTM and Zarzenda(R) willgive specialists a clinically proven first-line alternative to steroidtreatment." Prof. Dr. Wolfgang Kehr, CEO of Intendis added: "Zarzenda(R) is an important addition to our range of dermatological productsand one which we expect will help us to build not only on our significant globalpresence in the dermatology market, but also on our reputation as a partner ofchoice for quality in-licensed products like AtopiclairTM." - ends - Notes to Editors Sinclair Pharma plc is an international specialty pharmaceutical company. Ithas a growing sales and marketing operation that is already present in France,Spain, Italy and Portugal, and a complementary marketing partner network thatspans 60 countries. Sinclair focuses in niche/specialty therapeutic areas andits current portfolio focuses on products for dermatological conditions and oralhealth. Sinclair's goal is to become a sustainably profitable internationalpharmaceutical company, focusing in niche therapeutic areas, with a directcommercial presence in the key commercial markets. Sinclair Pharma plc is quoted on the Alternative Investment Market (AIM) on theLondon Stock Exchange. www.sinclairpharma.com Intendis, with more than 800 employees is a fully integrated pharmaceuticalcompany and was founded in January, 2005 as a subsidiary of Schering AG,Germany. It continued the dermatological business of Schering as afully-fledged, stand-alone dermatological company, building on the success andexpertise of its highly reputable products and people and currently has aturnover of €223 million p.a. Intendis is focused on delivering high qualityand innovative topical and systemic medicines, targeted to treat skin disordersand has a presence in Austria, Brazil, France, Germany, Italy, Japan, Mexico,Poland, Portugal, Russia, Spain, Turkey and USA. AtopiclairTM is Sinclair's non-steroidal cream indicated for relief andmanagement of the itching, burning and pain that patients experience with atopicdermatitis (AD) and allergic contact dermatitis (ACD). It is already approved inboth the US and the EU, and was the first prescription medical device authorisedby the US FDA to relieve the symptoms of AD and ACD. Recent independent studieshave established the effectiveness of AtopiclairTM in the treatment of bothadult and paediatric cases of AD and as a non- steroidal product AtopiclairTM iswell suited to the paediatric market. Atopic dermatitis (also known as eczema)is a chronic inflammatory disease that often has its onset in childhood. Sourcessuch as the American Medical Association and the New England Journal of Medicinecite paediatric rates of AD in Western countries at up to 20%. For further information please contact: Sinclair Pharma plc UKDr Michael Flynn, CEO Financial DynamicsJerry Randall ACA CFO Ben AtwellZoe McDougall, Corporate Communications John GilbertTel: +44 (0) 1483 410 600 Tel +44 (0) 207 831 3113 GermanyMC ServicesRaimund GabrielHilda JuhaszTel +49 89 210 228 0 "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Some or all of the statements in this document that relate to futureplans, expectations, events, performances and the like are forward-lookingstatements, as defined in the US Private Securities Litigation Reform Act of1995. Actual results of events could differ materially from those described inthe forward- looking statements due to a variety of factors. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma